|
|
 |
| |
Back to Scientific Program
Back to Annual Meeting
The Tolerability Of Tolterodine Is Not Diminished In Older Patients With Overactive Bladder: An Analysis Of 5 Randomized, Double-Blind, Placebo-Controlled Trials
David O Sussman1, Dale B. Glasser*2, Martin Carlsson*2
1University of Medicine and Dentistry of New Jersey, Stratford, NJ;2Pfizer, Inc, New York, NY
Introduction: The prevalence of overactive bladder (OAB) increases with age, yet OAB is underdiagnosed and undertreated in the older population. Tolterodine is an effective treatment for OAB in these patients; however, as with any pharmacotherapy, older persons may have special tolerability issues related to comorbidities and polypharmacy. We examined the tolerability profile of tolterodine extended release (TER) in older patients with OAB.
Methods: We compared the incidence of adverse events (AEs) among patients aged <65 (n=2526), ≥65 (n=1634), and ≥75 years (n=574) with OAB who received TER or placebo in 5 randomized, double-blind, placebo-controlled trials.
Results: There were no consistent differences in the incidence of TER-related AEs in older (≥65 or ≥75 y) vs younger (<65 y) patients (Table), nor were there treatment-related increases in withdrawal rates by age. The incidence of AEs was generally low, and most AEs were mild to moderate in severity. Dry mouth was the only AE that consistently occurred in >5% of patients who received TER (Table).
Conclusion: The nature and frequency of AEs associated with TER treatment were comparable across age groups. These data suggest that TER is a suitable first-line treatment for OAB in older patients. 
Back to Scientific Program
Back to Annual Meeting
|
|
| |
|
|
| |
|
|
|
|
